A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05451771` - Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis	Phase 1/Phase 2
Completed	`NCT02574676` - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Active, not recruiting	`NCT05199337` - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	Phase 1/Phase 2
Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
Completed	`NCT01409148` - Radioimmunoimaging of AL Amyloidosis	Phase 1
Active, not recruiting	`NCT04512235` - A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis	Phase 3
Recruiting	`NCT06383143` - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Completed	`NCT02632786` - The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis	Phase 2
Completed	`NCT02841033` - Daratumumab for the Treatment of Patients With AL Amyloidosis	Phase 1/Phase 2
Completed	`NCT04304144` - A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis	Phase 2
Recruiting	`NCT01408225` - Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Recruiting	`NCT04895917` - Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis	Phase 2
Terminated	`NCT02489500` - Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib	Phase 3
Completed	`NCT01570387` - A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis	Phase 1/Phase 2
Terminated	`NCT03154047` - Study in Subjects With Light Chain (AL) Amyloidosis	Phase 2
Completed	`NCT03236792` - Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis	Phase 1/Phase 2
Recruiting	`NCT04392960` - Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis	N/A
Recruiting	`NCT05898646` - Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial	Phase 2
Not yet recruiting	`NCT06022939` - Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	Phase 3

NCT number	NCT05277493
Study type	Observational [Patient Registry]
Source	Peking Union Medical College Hospital
Contact	Daobin Zhou, MD
Phone	69155020
Email	zhoudb@pumch.cn
Status	Recruiting
Phase
Start date	March 30, 2022
Completion date	September 2025

A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms